Sign In

Andrew Trister, MD PhD

Chief Medical & Scientific Officer advancing precision health @ Verily, an Alphabet company | ex-Apple, Gates Foundation

Dr. Andrew Trister, MD PhD, is a distinguished clinical leader and innovator with an extensive background spanning over twenty years in spearheading groundbreaking health technology projects in both the tech and healthcare sectors. His fervor lies in leveraging cutting-edge technologies and data to propel population health campaigns and augment access to impartial, superior, and personalized healthcare services. Currently, Dr. Trister holds the pivotal role of Chief Medical and Science Officer at Verily, where he steers the company's research, scientific, and population health endeavors, delivering his expertise across Verily's spectrum as the organization advances its precision health roadmap. Prior to his tenure at Verily, he assumed the position of Deputy Director of Digital Health and Artificial Intelligence at The Bill & Melinda Gates Foundation, pioneering the Foundation's foray into digital health and artificial intelligence to combat global health disparities. Preceding his role at the Gates Foundation, Dr. Trister played an instrumental role as a founding member of Apple's Health team, overseeing clinical research and machine learning collaborations with Apple's partners.

Highlights

Aug 9 · linkedin

It was great to speak at ASCO Breakthrough this week on how AI is impacting how we practice oncology.

The greatest potential I see for AI in healthcare is in improving, not replacing, what physicians can do for a patient. If as an industry we can get to a point where we’re using AI and data generated within the health system to make better decisions for the next patient, we can enable faster, more precise treatment for patients across the board.

I also enjoyed meeting many of my clinical colleagues and have been so impressed with the ways that they have leveraged technologies to address the hardest problems around drug discovery, care access, and equitable population management within oncology.

In case you missed the session, you can see more details here: [https://lnkd.in/gHH8GK3j]

Jul 11 · linkedin

The early warning system facilitated by wastewater testing proves invaluable in monitoring emerging pathogens, particularly in situations where clinical surveillance or active testing for a specific virus may be limited. We saw this recently come to life with the emergence of H5N1 and the Verily team’s development of an assay to detect H5 in wastewater samples. 

In a recent article, Megan Diamond discusses the public health opportunities of wastewater surveillance amid the H5N1 outbreak, emphasizing the effectiveness of this tool and the opportunities for the data to inform public health response. I continue to be encouraged by the continued investment we’re seeing in this space from organizations across both the public and private sector.

Andrew Trister, MD PhD
Add to my network

Location

Seattle, Washington, United States